跳至主要内容
临床试验/NCT05680974
NCT05680974招募中不适用

Gewinnung, Kultur Und Studien Von primären Humanen Zelltypen, Geweben Und Blut für Die Gezielte Behandlung Von Seltenen Hauterkrankungen

Johannes Kepler University of Linz1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2022年3月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
25
试验地点
1
主要终点
Improvement of disease as assessed by affected body surface area by 50 % upon off-label treatment with approved monoclonal antibody therapies

研究概览

简要总结

Rare skin diseases are generally defined as serious life-threatening, progressive chronic diseases of the skin that occur extremely rarely (i.e., 5 in 10,000 people are affected). More than 80% are hereditary. In most cases, late diagnosis and the lack of therapeutic strategies also contribute to severe disease progression. Therefore, new therapeutic options are urgently needed and with them knowledge of the underlying mechanisms of disease development.

The aim of this project is to better understand disease mechanisms and to identify new pathways and drug targets that will improve patient care or therapy. In order to investigate the mechanisms of disease development, it is necessary to isolate biological material, i.e. blood and affected skin tissue from patients. For this purpose, adults 18 years of age and older with a congenital rare skin disease are included. We take blood and (lesional) skin biopsies from patients to perform immunoprofiling, as well as cell biological studies with the patient's cells. The risk for the patients is low, as only peripheral blood and skin biopsies are taken. Potential risks include bruising and pain as well as infection, postoperative bleeding, wound infection or delayed wound healing, pain, and scarring.

The samples are pseudonymized and stored with the pseudonym only. Cells and skin samples are only preserved with the prior consent of the patient.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age of 18
  • rare disease is known or suspected
  • patent consent

排除标准

  • 未提供

结局指标

主要结局

Improvement of disease as assessed by affected body surface area by 50 % upon off-label treatment with approved monoclonal antibody therapies

时间窗: 12 months

Severely affected consenting patients will be treated with approved monoclonal antibodies targeting exactly the cytokines that are increased in the patient's lesional skin.

次要结局

未报告次要终点

研究者

发起方
Johannes Kepler University of Linz
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wolfram Hoetzenecker

Chair of the Department of Dermatology and Venerology

Johannes Kepler University of Linz

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Studies of Dermatologic Diseases Biospecimen Acquisition ProtocolDermatologic ConditionsHealthy VolunteersNormal VolunteersCarcinoma, Merkel Cell
NCT02471352National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)700
Unknown
不适用
The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin DiseasesInflammatory Skin Disease
NCT04937101Second Affiliated Hospital, School of Medicine, Zhejiang University78
已完成
不适用
Prevalence and Associated Factors of Skin Diseases among The Geriatric Outpatients in ThailandGeriatric population have been increasing importance expeditiously in the healthcare system. Epidemiology of skin disorders are interesting subjects to challenge physicians for comprehensive management in the elder wellness.The aim of the study is to find out the prevalence of the most frequent dermatologic disorders in the elderly outpatients and to identify their major associated determinants.skin diseases, elderly patients, geriatric outpatients, prevalence, associated factor
TCTR20220126007Faculty of Medicine Vajira Hospital521
招募中
不适用
Evaluate the Evolution of Body and Scalp Skin Discomfort in Patients With Hereditary Ichthyosis After Wraps (EnvelopIchtyose)Ichthyosis Inherited
NCT05979506University Hospital, Toulouse34
招募中
不适用
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin DiseasesPsoriasisCutaneous LupusCutaneaous SclerodermaNeutrophilic DermatosisCutaneous GranulomatosisActive LeprosyAtopic DermatitisLichen PlanusAutoimmune Bullous DermatosisCutaneous VasculitisHidradenitis SuppurativaDermatomyositis
NCT06599411Assistance Publique - Hôpitaux de Paris830
Personalized Therapy of Patients Suffering From Rare... | 临床试验